Read ARC’s latest radiation oncology news on the latest radiation technologies.

Exposure to CyberKnife Advertising is Associated with Over-Estimation of Objective Benefits Compared with other Prostate Cancer Treatments

There has been increased direct-to-consumer advertising for Cyberknife (CK), a brand of stereotactic radiotherapy for prostate cancer. Evidence comparing CyberKnife with other prostate cancer therapies is limited. Columbia University Medical Center physicians hypothesized that those viewing CyberKnife advertisements would have inaccurate impressions regarding its effectiveness and safety.…

Read More